Active clinical trial

Connectome Imaging in Aging and Dementia

Study Status: 
Active
Study Description: 

We're looking for adults with AD, FTD, MCI or cognitive complaints, ages 50-95!

 

The purpose of this research study is to look at brain connectivity in a variety of people with memory problems, including people with complaints about their memory and people diagnosed with a neurodegenerative disease, including Alzheimer’s disease (AD), fronto-temporal dementia (FTD), and mild cognitive impairment (MCI).

 

What to expect:

•     one 3-hour visit

•     Participants watch a movie during a one hour brain scan (MRI)

•     Questionnaires and memory testing

Study Coordinator(s): 

Nancy Coppelman

Tel:  617-643-5200

Aducanumab Study --- Coming Soon!

Study Status: 
Active
Study Description: 

Coming soon!

Study Coordinator(s): 

Nancy Coppelman

Tel:  617-643-5200

A Multi-Center, Double-Blind, Placebo-Controlled Phase II/III Study to Evaluate the Impact of Nasal-Inhaled Insulin in Participants with Mild Memory Impairment and Early Alzheimer's Disease (SNIFF)

Study Status: 
Active
Study Description: 

What is the SNIFF Study?

The purpose of the SNIFF study is to find out whether insulin, when administered as a nasal spray, improves memory in adults with a mild memory impairment or Alzheimer's disease (AD).  The rationale behind the study is growing evidence that insulin carries out multiple functions in the brain and that poor regulations of insulin may contribute to the development of AD. Insulin resistance, reduced cerebrospinal fluid insulin levels, and reduced brain insulin signals have been found in AD patients, suggesting that a therapy aimed at correcting these deficiences may be beneficial.

 

A study flyer with more details is attached.

Study Coordinator(s): 

Nancy coppelman

Tel:  617-643-5200

A Multi-Center, Double-Bind, Placebo-Controlled Phase IIa Study to Evaluate an Investigational Medicine to Treat Mild-Stage Alzheimer's Disease (CONNECT)

Study Status: 
Active
Study Description: 

The CONNECT study will test whether an oral, experimental drug, AZD0530 (Saracatinib), will slow progression in mild-stage Alzheimer's disease (AD). Although the cause of AD is unknown, several lines of evidence suggest that a peptide known as beta-amyloid plays a central role.  Convergent evidence in recent years has yielded a refinement of the "amyloid hypothesis", suggesting that neurotoxicity of beta-amyloid oligomers leads to Alzheimer's disease.

 

Researchers are looking for people who:

-- are 55-85 years of age,

-- have a diagnosis of mild Alzheimer's disease,

-- are willing to undergo a variety of clinic assessments,

-- have a study partner willing to attend clinic visits and have at least 10 hours/week of contact with study participant.

 

A study flyer with more details is attached.

Study Coordinator(s): 

Nancy Coppelmen

Tel:  617-643-5200

β-Amyloid Production and Effects on Cognition Study (APECS)

Study Status: 
Active
Study Description: 

If you have noticed changes in your memory over the last year and are wondering if it is a normal part of again or if it something more serious, you may be interested in a clinical research study. This study is evaluating an oral investigational medication that may help slow down the progression of what could be very early Alzheimer's disease.

 

To participate, you must:

-- be between 50 and 85 years of age,

-- have had memory problems for at least one year,

-- have someone in your life that can attend study visits with you and help you follow study requirements.

 

A study flyer with more details is attached.

Study Coordinator(s): 

Nancy Coppelman

Tel:  617-643-5200

Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)

Study Status: 
Active
Study Description: 

The purpose of this clinical trial is to evaluate the efficacy, safety and tolerability of solaneuzumab, a drug that may have the potential to slow the onset of Alzheimer's disease (AD). In AD, there are abnormally high levels of a protein, called amyloid in the brain. We hope that solaneuzumab can reduce the amount of amyloid in the brain.

 

We are looking for participants who:

-- do not have memory problem

-- are between age 65 and 85

-- have a reliable caregiver or family member who knows them well

-- are in stable medical condition

-- are willing to undergo MRI and PET scans

 

More information about the national study may be found at http://a4study.org/

Check out the study's video at: http://a4study.org/video

Study Coordinator(s): 

Nancy Coppelman

Tel:  617-643-5200

Disentangling the Contribution of Tau to Aging, Dementia, and Neurodegeneration

Study Status: 
Active
Study Description: 

The purpose of this study is to determine the presence of the protein Tau in the brain in a variety of populations, ranging from healthy adults to those diagnosed with a neurodegenerative disease.

 

What to expect:

-- 8-month study

-- Memory testing

-- MRI scans

-- PET scans

-- Blood work

-- Optional:  Lumbar puncture

 

Study Coordinator(s): 

Nancy Coppelman

Tel:  617-643-5200

A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-Finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects with Early Alzheimer's Disease (BAN2401-G000-201)

Study Status: 
Active
Study Description: 

What is the purpose of this research study?

The purpose of this clinical trial is to evaluate the efficacy, safety and tolerability of BAN2401, a drug that may have the potential to treat Alzheimer's disease (AD). In AD, there are abnormally-high levels of a protein, called amyloid beta, in the brain. We hope that BAN2401 can reduce the amount of amyloid.

 

Who is eligible?

We are looking for participants who:

-- have been diagnosed with Mild Cognitive Impairment (MCI) or mild Alzheimer's disease dementia

-- are between the age of 50 and 90

-- have a reliable caregiver or family member who knows them well and is able to accompany them to study visits

-- are in stable medical condition

-- are willing to undergo MRI and PET scans and optional lumbar punctures

 

People taking approved Alzheimer's medications (donepezil/Aricept, galantamine/Razadyne, rivastigmine/Exelon, memantine/Namenda) are eligible to take part in this study and can continue taking these medications during the study.

 

A study flyer with more details is attached.

Study Coordinator(s): 

Nancy Coppelman

Tel:  617-643-5200

Olfactory Deficits in Neurological Disease

Study Status: 
Active
Study Description: 

We are seeking healthy adults, aged 18 or older, to participate in a research study. The goal of the study is to examine olfactory function (or the sense of smell) in healthy individuals and in preclinical and clinical subjects with Alzheimer's Disease, Dementia with Lewy Bodies, or Frontotemporal Dementias.

 

If you qualify, you will be asked to undergo tests that measure your ability to discriminate, identify, remember, and evaluate a group of everyday odors. The study will take place at the Departments of Neurology or Psychiatry of the Massachusetts General Hospital (either on the Charlestown Navy Yard or the main campus of the hospital). It will take approximately one hour to complete the tests.

 

You will be asked to do this once a year. You will not be paid for participating in the study.

Study Coordinator(s): 

Ilaria Amato

Tel: 617-724-7401

The Harvard Aging Brain Study (HABS)

Study Status: 
Active
Study Description: 

 We are seeking healthy adults, 50 to 65, or 80 to 90 years of age to participate in a research study. The purpose of the study is to develop ways for understanding brain changes affecting memory and thinking that occur with age.

 

Participants will be asked questions about their memory and thinking and must have a friend or relative who can answer 30 minutes of questions about your day-to-day activities.  If you qualify, you will be asked to have 8 brain scans at year 1 and 3, follow-up memory and thinking testing as well as blood draws annually for five years (at 12, 24, 36, 48 & 60 monhts) after the initial visit.

 

You may also participate in an optional study where you will have 2 lumbar punctures (spinal taps).

 

All evaluations will be free of cost and reimbursement for time and transporation is $1600.

Study Coordinator(s): 

Nancy Coppelman

Tel:  617-643-5200

Syndicate content